Heraldo de Madrid - Onco-Innovations Announces U.S. Listing on the OTCQB Market

The listing on the OTCQB is a step in enhancing the Company's visibility and accessibility for U.S. investors. This milestone is expected to expand Onco-Innovations' visibility in the U.S. investment market.

"This listing marks a significant milestone for Onco-Innovations, allowing us to engage more effectively with U.S. investors and offering us the ability to expand our shareholder base. We are committed to driving innovation in oncology and believe this increased accessibility will support our long-term growth," said Thomas O'Shaughnessy, CEO of the Company.

The OTCQB Venture Market provides an established platform for early-stage and growth companies to enhance their visibility in the U.S. market. Real-time quotes and market information on Onco-Innovations can be found at www.otcmarkets.com.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to and the potential benefits of the Company's shares being posted for trading on the OTCQB, and the Company's prospects and business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to expand the Company's shareholder base or to attract U.S. investment interest, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

L.Herrero--HdM